Table 1.

Baseline characteristics for the intent-to-treat infected population

CharacteristicaValue for group receiving:
PeramivirOseltamivir (n = 365)
300 mg (n = 364)600 mg (n = 362)
Region/countryb
    Japan247 (67.9)249 (68.8)246 (67.4)
    Taiwan81 (22.3)79 (21.8)84 (23.0)
    South Korea36 (9.9)34 (9.4)35 (9.6)
Male sex180 (49.5)198 (54.7)184 (50.4)
Age (yr)
    Mean ± SD34.9 ± 11.735.9 ± 12.034.6 ± 11.7
    Range20–7820–7820–80
Wt (kg)
    Mean ± SD61.50 ± 13.0462.69 ± 13.0561.59 ± 13.09
    Range39.5–120.033.4–104.740.0–140.1
Smokingb113 (31.0)111 (30.7)112 (30.7)
Coexisting disease at baseline127 (34.9)146 (40.3)132 (36.2)
Receipt of drugs from onset of influenza to randomization206 (56.6)212 (58.6)211 (57.8)
Influenza vaccination64 (17.6)56 (15.5)63 (17.3)
Duration of influenza
    0-12 h33 (9.1)24 (6.6)30 (8.2)
    >12-24 h129 (35.4)117 (32.3)131 (35.9)
    >24-36 h94 (25.8)114 (31.5)107 (29.3)
    >36-48 h108 (29.7)106 (29.3)95 (26.0)
    >48 h0 (0.0)1 (0.3)2 (0.5)
Composite symptom score (mean ± SD)b12.5 ± 3.412.5 ± 3.312.5 ± 3.2
Body temp (°C) (mean ± SD)38.53 ± 0.4938.48 ± 0.4938.56 ± 0.52
Result of rapid antigen testb
    A335 (92.0)333 (92.0)338 (92.6)
    B27 (7.4)29 (8.0)25 (6.8)
    A and B2 (0.5)0 (0.0)2 (0.5)
Influenza virus subtype
    A/H1197 (54.1)200 (55.2)201 (55.1)
    A/H1, H30 (0.0)0 (0.0)1 (0.3)
    A/H3112 (30.8)108 (29.8)108 (29.6)
    A/−21 (5.8)15 (4.1)17 (4.7)
    B21 (5.8)26 (7.2)23 (6.3)
    Unknown13 (3.6)13 (3.6)15 (4.1)
  • a Unless otherwise indicated, each value is the number (percentage) of patients with the characteristic.

  • b Randomization ensured balance for this factor.